TEMPO ( Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease ) reported at the American Society of Nephrology meeting in San Diego last week.Anna Soubry, the Parliamentary under Secretary of State for Public Health congratulated her honourable friend on securing the debate and paid tribute to the excellent work undertaken by the Polycystic Kidney Disease charity. Anna Soubry went on to emphasise the importance of raising awareness of Chronic Kidney Disease, commenting that although 2.3 million people are now on primary care registers for CKD in England there is more work to do. She underlined the importance of research, citing the three studies, which are being hosted by the National Institute for Health Research, and drawing MPs attention to the
The Minister concluded by speaking about the importance of the quality of life in people with chronic kidney disease. Drawing attention to the Quality Standard for CKD published last year by NICE , which clearly states that patients with a genetic family history of Polycystic Kidney Disease should have access to specialist care, and support to optimise their quality of life and clinical outcomes.